Clinical Effect of Xiaochaihu Decoction Combined with Acupuncture in the Treatment of Syndrome of Fullness and Oppression
Objective To explore the clinical effect of Xiaochaihu decoction combined with acupuncture in treating syndrome of fullness and oppression.Methods A total of 60 patients with cirrhosis in Chinese Medicine Hospital of Puyang from May 2021 to June 2023 were randomly divided into two groups,with 30 cases in each group.Both groups were given routine treatment.On this basis,the control group received acupuncture treatment,and the observation group received Xiaochaihu decoction combined with acupuncture treatment,both of which were treated continuously for 4 weeks.The clinical efficacy,TCM syndrome scores,main frequency and amplitude of electrogastrogram,gastrointestinal hormones[somatostatin(SS),gastrin(GAS),motilin(MOT)],LPS/TLR4/NF-κB pathway related factors[lipopolysaccharides(LPS),Toll-like receptor 4(TLR4),nuclear factor-κB(NF-κB)]were compared between the two groups,and safety was evaluated.Results The total clinical effective rate in the observation group was higher than that in the control group(P<0.05).After 2 and 4 weeks of treatment,the main symptoms,secondary symptoms and total score of the observation group were lower than those of the control group(P<0.05).After 2 and 4 weeks of treatment,the observation group showed higher levels of GAS and MOT compared to the control group,and lower levels of SS compared to the control group(P<0.05).Treatment for 2 and 4 weeks,LPS,TLR4,NF-κB level of observation group was lower than that of the control group(P<0.05).During the treatment period,neither group experienced significant adverse reactions.Conclusion Xiaochaihu decoction combined with acupuncture may relieve the clinical symptoms of edema,regulate gastrointestinal hormone and function by regulating LPS/TLR4/NF-κB pathway,and the therapeutic effect is significant,which can improve the quality of life.
syndrome of fullness and oppressionTCM syndrome scoreXiaochaihu decoctionacupunctureLPS/TLR4/NF-κB pathway